In the News

New living guideline offers advice on medications for type 2 diabetes

The risk-stratified recommendations, developed by an international panel for the BMJ Rapid Recommendations series, are intended to help physicians and patients choose among sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, finerenone, and tirzepatide.

Semaglutide, tirzepatide showed improved outcomes in patients with HF and diabetes

Risk for heart failure (HF) hospitalization or all-cause mortality was more than 40% lower in patients with type 2 diabetes and HF with preserved ejection fraction who took semaglutide or tirzepatide compared to those who took sitagliptin (a placebo proxy), a study found.

Statins provided primary prevention benefit in younger patients with type 1 diabetes

Researchers used a British database to conduct a target-trial emulation assessing the benefits of statin initiation in type 1 diabetes patients with a mean age of 45 years. They found significant decreases in 10-year risk of all-cause mortality and cardiovascular disease in those who took statins.

MKSAP quiz: Recurrent dizziness

This month's quiz asks readers to evaluate and manage a 65-year-old man with type 1 diabetes and recurrent dizziness when getting up from a chair.

Spotlight on metals and medications

One study found that patients taking metformin had lower levels of copper and iron and higher levels of zinc, while another showed that use of sodium-glucose cotransporter-2 inhibitors was associated with lower rates of iron deficiency anemia than dipeptidyl peptidase-4 inhibitors.

Diet plus exercise significantly reduced progression to diabetes in Spanish trial

For adults ages 55 to 75 years with metabolic syndrome and overweight or obesity, an intervention that included calorie reduction, the Mediterranean diet, and increased physical activity reduced diabetes incidence by 31% over six years compared to the Mediterranean diet alone.

In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y

The improvement in maximum walking distance seen with semaglutide was comparable to that found with the only approved pharmacologic agent for claudication, but less than what can be achieved through supervised exercise therapy, an ACP Journal Commentary said.

Diabetes devices recalled, generics approved

Speaker issues were reported with an insulin pump and glucose monitoring system, and the first generic versions of exenatide and liraglutide were approved.